ProjectA Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects…
Basic data
Title:
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma
Duration:
24/02/2016 to 23/02/2019
Abstract / short description:
A Multicenter, Phase 1/1b, Open-Label,
Dose-Escalation Study of ABBV-838, an Antibody
Drug Conjugate, in Subjects with Relapsed and
Refractory Multiple Myeloma
Dose-Escalation Study of ABBV-838, an Antibody
Drug Conjugate, in Subjects with Relapsed and
Refractory Multiple Myeloma
Keywords:
clinical trial
klinische Studie
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Centers or interfaculty scientific institutions
Contact persons
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Wiesbaden, Hessen, Germany